Jazz Pharmaceuticals plc Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax
Jazz Pharmaceuticals plc (JAZZ) reported Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterReclassificationAdjustmentTax · last filed 2024-02-28
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for the quarter ending 2022-12-31 was $0.00.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for the quarter ending 2022-09-30 was $0.00.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for the quarter ending 2022-06-30 was $0.00.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for fiscal 2023 was $0.00.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for fiscal 2022 was $0.00.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for fiscal 2021 was -$43.00K.
- Jazz Pharmaceuticals plc other comprehensive income (loss), financial liability, fair value option, after reclassification adjustment, tax for fiscal 2020 was $0.00.
| Period end | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 3 month as first filed | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 9 month as first filed | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Reclassification Adjustment, Tax 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | -$140.00K derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | -$140.00K derived: sum of 3 quarters · filed 2024-02-28 | -$168.00K derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | -$140.00K derived: sum of 2 quarters · filed 2024-02-28 | -$168.00K derived: sum of 3 quarters · filed 2024-02-28 | -$293.00K derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$168.00K derived: sum of 2 quarters · filed 2024-02-28 | -$293.00K derived: sum of 3 quarters · filed 2024-02-28 | -$43.00K 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$28.00K 10-Q · filed 2022-11-09 | $28.00K 10-Q · filed 2021-11-09 | -$153.00K derived: sum of 2 quarters · filed 2022-11-09 | $97.00K 10-Q · filed 2022-11-09 | -$97.00K 10-Q · filed 2021-11-09 | -$150.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$125.00K 10-Q · filed 2022-08-03 | -$125.00K 10-Q · filed 2022-08-03 | -$122.00K derived: sum of 3 quarters · filed 2023-03-01 | -$122.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-04 | $3.00K derived: sum of 2 quarters · filed 2023-03-01 | $3.00K derived: sum of 3 quarters · filed 2023-03-01 | $3.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |